Skip to main content

ERC

Publications

  • Participate
    • Patients
    • Doctors
    • Investors
  • Products
    • Gliovac/ERC1671
  • Media
    • News
    • Publications
  • About
    • Executive Management
    • Executive board
    • Scientific board
    • Milestone achievements
  • Contact
NewsPublications
Jul2022
Cohort Study of GLIOVAC/ERC1671/SITOIGANAP to treat Glioblastoma
Aug2018
Review - Therapeutic Immunization against Glioblastoma – Virgil Schijns
Aug2018
Phase II study of ERC1671/SITOIGANAP plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts.
Jan2018
Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat
Oct2015
Use of ERC-1671/SITOIGANAP Vaccine in a patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report.
May2015
Therapeutic vaccination against malignant gliomas Q1 based on allorecognition and syngeneic tumor antigens: Proof of principle in two strains of rat.
Apr2015
First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined all- and auto-immune tumor reactivity.
Jul2012
Cancer Immunology.
May2012
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation
May2010
Immunotherapy of Malignant Gliomas using autologous and allogeneic tissue cells.
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Cookie and Privacy Policy for more details.
Close
Copyright © 2001-2023 ERC.SA. All rights reserved.
Made byKonnu
Cookie and Privacy PolicyTerms & Conditions
Top